tregs
(2)
Andy Walker
Andy Walker is a chemical engineer turned biotech operator who co-founded GentiBio, a Cambridge-based company engineering regulatory T cells (EngTregs) to functionally cure autoimmune and autoinflammatory diseases. He started as the company's CTO, moved through President and COO, and became President and CEO in 2024. Before GentiBio he ran manufacturing for cell and protein therapeutics at Juno Therapeutics and led Jewel Biotherapeutics. He holds a PhD in chemical engineering from UC Berkeley and a BS from the University of Washington.
Jason Cole
Jason F. Cole is the founding CEO and board member of Zag Bio, a Cambridge, Massachusetts biotech that launched in October 2025 with $80 million to develop thymus-targeted medicines for autoimmune diseases, starting with Type 1 diabetes. A lawyer by training with a J.D. from Columbia and an A.B. in Government from Dartmouth, Cole has spent more than two decades in biotech operations and finance. At bluebird bio he helped grow the company from roughly 100 to 1,200 employees, raised over $3.7 billion in equity financings, and helped deliver multiple first-in-class gene and cell therapies to patients. He most recently led SalioGen Therapeutics as CEO and Board Chair, and serves as Vice Chair of the MassBio board.